BioInvent International AB (BINV)

Currency in SEK
2.940
+0.190(+6.91%)
Closed·
BINV is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.6752.945
52 wk Range
1.90034.750
Key Statistics
Prev. Close
2.94
Open
2.745
Day's Range
2.675-2.945
52 wk Range
1.9-34.75
Volume
307.51K
Average Volume (3m)
385.12K
1-Year Change
-90.1672%
Book Value / Share
3.05
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BINV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
56.067
Upside
+1,807.03%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

BioInvent International AB News & Analysis

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 56.067
(+1,807.03% Upside)

BioInvent International AB Earnings Call Summary for Q3/2026

  • BioInvent shares plummeted 71.5% to $5.90 amid financing concerns; Q3 cash of SEK 225M funds operations only through Q1 2027 without rights issue.
  • Q3 net sales rose to SEK 10.8M from SEK 3.3M YoY, but nine-month sales fell to SEK 37M from SEK 224M due to absence of prior-year milestone payments.
  • Lead drug BI-1808 showed 24% response rate in ovarian cancer; randomized Phase I/IIa study to start Q1 2027 with interim data expected H2 2027.
  • Planned rights issue of SEK 430M gross would extend cash runway through end-2027; secured portion of SEK 350M already committed by investors.
  • CEO Welschof positioned BI-1808 as first-in-class TNFR2-targeting immunotherapy, calling it 'next version of pembrolizumab' amid active partnering talks.
Last Updated: 29/10/2026, 16:46
Read Full Transcript

Earnings

Latest Release
Oct 29, 2026
EPS / Forecast
-1.81 / -1.98
Revenue / Forecast
10.79M / 8.01M
EPS Revisions
Last 90 days

BINV Income Statement

Compare BINV to Peers and Sector

Metrics to compare
BINV
Peers
Sector
Relationship
P/E Ratio
−0.4x−15.8x−0.2x
PEG Ratio
0.01−0.150.00
Price/Book
0.9x4.3x2.6x
Price / LTM Sales
4.5x7.7x2.7x
Upside (Analyst Target)
-502.3%66.0%
Fair Value Upside
Unlock20.5%10.8%Unlock

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin’s lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1/2a clinical trial for the treatment of solid tumors. It has a collaboration with Transgene oncolytic virus platform with BioInvent proprietary antibodies; MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers; AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence; and XOMA. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.

Employees
107
Market
Sweden

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
401.43K0.61%1.10M
Other Institutional Investors
41.40M62.91%113.84M
Public Companies & Retail Investors
24.01M36.48%66.02M
Total
65.8M100.00%180.96M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Redmile Group, LLC15.23%10,018,75627,552
Van Herk Investments B.V.13.84%9,105,58925,040

People Also Watch

121.39
INSM
-1.22%
172.83
ATI
-0.26%
432.06
CMI
-0.15%
165.39
NBIX
+0.05%
69.81
CORT
+0.85%

FAQ

What Is the BioInvent International (BINV) Stock Price Today?

The BioInvent International stock price today is 2.940 SEK.

What Stock Exchange Does BioInvent International Trade On?

BioInvent International is listed and trades on the Stockholm Stock Exchange.

What Is the Stock Symbol for BioInvent International?

The stock symbol for BioInvent International is "BINV."

What Is the BioInvent International Market Cap?

As of today, BioInvent International market cap is 180.960M SEK.

What Is BioInvent International's Earnings Per Share (TTM)?

The BioInvent International EPS (TTM) is -7.40.

When Is the Next BioInvent International Earnings Date?

BioInvent International will release its next earnings report on Mar 04, 2027.

From a Technical Analysis Perspective, Is BINV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has BioInvent International Stock Split?

BioInvent International has split 8 times.

How Many Employees Does BioInvent International Have?

BioInvent International has 107 employees.

What is the current trading status of BioInvent International (BINV)?

As of Nov 17, 2026, BioInvent International (BINV) is trading at a price of 2.940 SEK, with a previous close of 2.940 SEK. The stock has fluctuated within a day range of 2.675 SEK to 2.945 SEK, while its 52-week range spans from 1.900 SEK to 34.750 SEK.

What Is BioInvent International (BINV) Price Target According to Analysts?

The average 12-month price target for BioInvent International is 56.067 SEK, with a high estimate of 90 SEK and a low estimate of 4.3 SEK. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +1,807.03% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.